Introduction
============

Each year an estimated 50 million travelers visit malaria endemic areas ([@b13-tcrm-4-1105]) and 10,000--30,000 of them fall ill with malaria after returning home ([@b8-tcrm-4-1105]; [@b20-tcrm-4-1105]). This imported malaria, which represents an important public health problem with a high mortality rate ([@b10-tcrm-4-1105]), can be easily treated if diagnosed promptly, and it follows a serious course in only about 12% of individuals ([@b4-tcrm-4-1105]).

The risk of infection varies considerably, depending on the degree of endemicity, the duration of stay, individual behavior, and preventive measures taken ([@b16-tcrm-4-1105]). Risk is especially high in tropical Africa, where 80%--95% of infections are caused by *Plasmodium falciparum* ([@b17-tcrm-4-1105]), the most serious form. Most cases of falciparum malaria occur because of poor adherence to or complete failure to use chemoprophylaxis, combined with failure to take adequate precautions against mosquito bites ([@b20-tcrm-4-1105]).

Malaria control must be an essential part of health care programs provided by companies operating abroad in malarious areas. This is especially important considering that travelers from malaria-free regions going to endemic areas are highly vulnerable as they have little or no immunity, and are often exposed to delayed or wrong diagnosis when returning to their home country ([@b19-tcrm-4-1105]).

Many companies have in-house medical departments providing the necessary assistance. Italian-based Saipem, a subsidiary of the Eni Group, is a case in point. In compliance with Italian law 626/94, the company has implemented a specific program for the prevention and control of malaria in the case of workers traveling to or residing in high risk endemic areas. Besides receiving pre-travel educational materials and medical advice, Saipem's personnel are offered chemoprophylactic treatment with atovaquone and proguanil hydrochloride (Malarone^®^; Glaxo-SmithKline) as effective chemoprophylactic regimen appropriate for subjects bound to malaria-endemic destinations. The fixed-dose combination of atovaquone and proguanil (A/P) has been reported to be highly effective for prophylaxis of malaria caused by *P. falciparum* ([@b14-tcrm-4-1105]; [@b2-tcrm-4-1105]) having an excellent safety profile during both prophylaxis and treatment courses ([@b2-tcrm-4-1105]).

In the case of individuals undergoing malaria prophylaxis while on duty, it is important that the treatment chosen has no negative effects that may interfere with their performance With respect to this, the choice of A/P appears to be more advantageous compared to other antimalarials such as mefloquine and chloroquine for which severe neuropsychiatric disturbances have been reported in approximately 1 in 10,000 travelers ([@b20-tcrm-4-1105]).

The present study is a questionnaire-based survey that was conducted on a sample of healthy travelers to remote worksites in malarious areas. The aim was to obtain some insights into A/P compliance in the attempt to acquire real-world data on the acceptability and tolerability of A/P treatment from the traveler's point of view.

Participants and methods
========================

A total of 700 Saipem's healthy employees (643 males and 57 females) traveling to malaria-endemic areas (Nigeria, Republic of the Congo, Angola) in the period from January 2007 to November 2007 were eligible for inclusion in the study. Duration of trip was 7 days on average.

Subjects were consecutively enrolled from a larger group of Saipem's employees who voluntarily agreed to participate in the study. Just before departure, all subjects underwent clinical examination and referred to the Saipem medical department where they received pretravel advice on appropriate measures of individual protection, chemoprophylaxis, and treatment. In concomitance with the counseling, they were administered a paper questionnaire by Saipem's travel medicine specialist with the aim of gathering data on the use, management, and effects of A/P chemoprophylaxis.

The questionnaire, which was provided with detailed instructions to ensure accurate completion, consisted of 16 questions to be entered after departure from the malarious area. The information requested regarded demographic data (age, sex, education), information on personal knowledge of malaria prevention/chemoprophylaxis, and possible use of antimalarial drugs in the past. The second part included questions on A/P chemoprophylaxis: ease of use, adherence to the prescribed regimen, and experience of adverse side-effects.

All 700 questionnaires were entered into a database and analyzed. Statistical analysis was performed using Student's t-test to compare average data of quantitative variables between patients who had either already traveled or were traveling for the first time as Saipem's employees to a malaria-endemic area. Statistical significance of differences in distribution frequency was tested by chi-square test (Pearson) and analysis of contingency tables. A p value of \<0.05 was considered to be statistically significant. Analysis was carried out using statistical package SPSS 10.0 (SPSS Inc. Chicago).

Results
=======

All 700 travelers completed the questionnaires in all their parts for a response rate of 100% and delivered them to Saipem's medical department on their return. Of these, 85% were returned in electronic form and the remainder (15%) on paper. Ninety percent of the respondents were habitual travelers, whereas 10% were on their first visit to a malarious region as employees of Saipem. Most were male (92%) in both groups. Mean age was 38.3 years in the group of habitual travelers and 30.7 in those traveling for the first time. Most had a high educational background: tertiary school (22%) or first degree or post-degree specialization (77%). Compliance was extremely high as 99.6% of subjects adhered to the A/P chemoprophylactic regimen, which required 1 adult tablet (atovaquone 250 mg + proguanil hydrochloride 100 mg) daily beginning 1--2 days before exposure, throughout exposure, and continuing 7 days after departure from the malaria-endemic area ([@b3-tcrm-4-1105]). Only 3 individuals were not compliant, and the reason for failing to adhere was explained as low perception of malaria exposure risk ([Table 1](#t1-tcrm-4-1105){ref-type="table"}).

Of the habitual travelers, most (88.5%) had used chemoprophylaxis with A/P on previous occasions (mean number of times 2.4) and for only 72 of them (11.5%) this was the first time they had experienced A/P prophylaxis. Nearly all habitual travelers (96.5%) had taken other anti-malarials on past occasions, namely mefloquine (67.7%), proguanil (12.6%), chloroquine (12.5%), and doxycycline (7.3%). Among first-time travelers only mefloquine (n = 30; 100%) was indicated as medication previously used as an antimalarial ([Table 2](#t2-tcrm-4-1105){ref-type="table"}).

When asked about the reason for choosing A/P as anti-malarial chemoprophylaxis, 44% of the habitual travelers and 59% of first-time travelers responded that they were following medical advice. For an equal proportion in both groups (23%) the reason was because they were aware of the regimen benefits. Twenty-two percent of the habitual travelers compared with about 10% in the other group admitted having chosen A/P for the fewer adverse side-effects. Better sense of protection against the disease was the answer chosen by 10 % of habitual travelers against 8% of first-time travelers ([Figures 1](#f1-tcrm-4-1105){ref-type="fig"} and [2](#f2-tcrm-4-1105){ref-type="fig"}).

When asked to highlight possible differences with other antimalarial drugs, the group of habitual travelers generally declared having experienced much fewer (85.2%) or rather fewer (14.8%) adverse side-effects. Condition of administration was generally well accepted, being very easy (5.5%) and rather easy (94.5%) to manage. In terms of sense of protection against the disease, most had felt rather (77.2%) and much (22.8%) more protected if compared with previous other prophylactic treatments ([Table 3](#t3-tcrm-4-1105){ref-type="table"}). The most common adverse reaction was abdominal pain in both habitual travelers (n = 61) and first-time travelers (n = 24), followed by few cases of headache and nausea. No serious adverse reactions were reported ([Table 4](#t4-tcrm-4-1105){ref-type="table"}).

Discussion
==========

Past studies, recently reviewed by [@b2-tcrm-4-1105] have proved A/T efficacy and optimum safety profile, considering also its advantage over other antimalarial drugs in terms of efficacy against multidrug-resistant *P. falciparum* malaria.

Our aim, however, was to assess the impact of A/P chemoprophylaxis in actual conditions of usage with particular attention to ease of use, individual capacity to comply with the regimen prescribed, and experience of adverse reactions. Of note, the survey was carried out on a considerably large sample (n = 700), if compared with available studies, whose samples do not usually exceed 150 included subjects.

Our findings are in line with other published data for safety and tolerability ([@b14-tcrm-4-1105]; [@b13-tcrm-4-1105]; [@b16-tcrm-4-1105]), in that A/P prophylaxis was well tolerated, with only mild to moderate adverse side-effects -- namely, those reported by the manufacturer -- and no serious adverse reactions. We may speculate that the lack of important adverse reactions may have favored better adherence to the regimen prescribed as shown by the high proportion of travelers who reported regular chemoprophylaxis. As noted in a number of studies including the paper by [@b6-tcrm-4-1105], non-adherence to chemoprophylactic regimens is in fact frequently secondary to drug side effects. Furthermore, in a study by [@b9-tcrm-4-1105] fewer recipients of A/P discontinued treatment because of adverse events than individuals receiving chloroquine plus proguanil or mefloquine. Most importantly, no A/P-related neuropsychiatric disturbances were reported. These findings reflect those of previous studies demostrating a lower frequency of neuropsychiatric adverse events with A/P compared with mefloquine ([@b11-tcrm-4-1105]). Considering that approximately 1 in 10,000 travelers receiving mefloquine or chloroquine prophylaxis experience severe neuropsychiatric disturbances ([@b20-tcrm-4-1105]), our results suggest that A/P may be considered a valuable therapeutic option especially when treatment concerns subjects on duty where physical and mental fitness is a prerequisite for their safety ([@b16-tcrm-4-1105]).

Compared with other available antimalarial drugs, prophylaxis with A/P appears to have appreciable advantages in terms of administration schedule and duration of recommended treatment. This aspect may also have favored the good level of adherence recorded. In fact, A/P prophylaxis can be started only 1--2 days before exposure and, above all, since the drug has casual prophylactic activity against the hepatic stages of *P. falciparum* ([@b15-tcrm-4-1105]), it can be discontinued 7 days after departing a malarious region ([@b14-tcrm-4-1105]), compared with 4 weeks with other antimalarials. This more convenient dosage regimen, particularly in the post-travel period, should not be undervalued, considering that good chemoprophylaxis does reduce the risk of fatal disease ([@b20-tcrm-4-1105]) especially in non-immune or semi-immune subjects when they return to their home country and that adherence rates for 4 weeks post exposure are generally low ([@b3-tcrm-4-1105]).

Though it is noteworthy that the survey was conducted on a large sample, it is necessary to point out some limitations that suggest cautious interpretation of the findings observed.

Treatment adherence was found to be very high (99%), which was probably the result of an overestimation because of the method employed. Questionnaire assessment, though widely used, has in fact some limitations because returning travelers tend to forget precise date and time of drug intake and over-report the correct regimen in an effort to please the investigator or to hide one's failure ([@b7-tcrm-4-1105]).

As for the side effects reported, it must be noted that monitoring was focused more on acute events, since questionnaires were delivered on return from the endemic area. As a consequence, under-reporting is likely to have occurred, especially on adverse reactions that emerged after some period of time. Moreover, it was not possible to assess possible interactions with other drugs as no specific medical data were collected from the sample. A further limitation is that our study lacks a control group using a different chemoprophylaxis and that most subjects included were male.

Nonetheless, data gathered from such a large number of subjects may be helpful in providing new insights into the real acceptability of A/P chemoprophylaxis. In the future it would be worth investigating further its good tolerability profile and more convenient dosage regimen in well-designed studies to prove their value in promoting better adherence and thus better efficacy.
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###### 

Characteristics of study population

                                                                   Habitual traveler   First-time traveler   Total                                                               
  --------------------------------------- ------------------------ ------------------- --------------------- ------- ----- ---- ------- ------ ----- ----- ------- ------ ------ ----------
  Age                                                                                                        38.3    7.7                30.7   2.9                 37.5   7.72   \<0.0001
  Sex                                     Male                     580                 92.5                                63   86.3                 643   91.9                  
                                          Female                   47                  7.5                                 10   13.7                 57    8.1                   
  Education                               Degree/post-degree       464                 74.0                                73   100.0                537   76.7                  
                                          Tertiary                 154                 24.6                                                          154   22.0                  
                                          Secondary                9                   1.4                                                           9     1.3                   
  Traveler to malarious areas             Habitual                 627                 100.0                                                         627   89.6                  \<0.0001
                                          First-time                                                                       73   100.0                73    10.4                  
  Was chemoprophylaxis regularly taken?   Yes                      625                 99.7                                72   98.6                 697   99.6                  
                                          No                       2                   0.3                                 1    1.4                  3     0.4                   
  If no, specify reason                   Low perception of risk   2                   100.0                               1    100.0                3     100.0                 

###### 

History of chemoprophylaxis in study population

                                                                                       Habitual traveler   First-time traveler   Total                                                                 
  ----------------------------------------------------------------------- ------------ ------------------- --------------------- ------- ------ ------ ------- -- ----- ------ ------ ----- ---------- ----------
  Is this the first time you used A/P?                                    No           555                 88.5                                 73     100.0            555    79.3                    \<0.0001
                                                                          Yes          72                  11.5                                                         145    20.7                    
  If no, how many times did you use A/P in the past?                                                                             2.4     1.28                                         2.4   1.28       
  Did you use other antimalarials other than A/P in previous occasions?   Yes          605                 96.5                                 30     42.3             635    91.0                    \<0.0001
  No                                                                      22           3.5                                               41     57.8              63    9.0                            
  If yes, specify which ones                                              Mefloquine   409                 67.7                                 30     100.0            626    68.7                    
  Proguanil                                                               76           12.6                                                                       111   12.2                \<0.0001   
  Chloroquine                                                             76           12.5                                                                       110   12.1                           
  Doxycycline                                                             44           7.3                                                                        64    7.0                            

**Abbreviation:** A/P, atovaquone/proguanil combination.

###### 

Atovaquone/proguanil chemoprophylaxis compared with other antimalarials

                                                                                                                                      Habitual traveler   First-time traveler   Total                                                                
  ------------------------------------------------------------------------------------------------------ ---------------------------- ------------------- --------------------- ------- ------ --- ------ ------- ------ ------ ------ ------ ------ --
  What differences did you experience between A/P and other antimalarials taken in previous occasions?   Fewer adverse side-effects   522                 85.2                  91      14.8   4   80.0   1       20.0   526    85.1   92     14.9   
  Ease of administration                                                                                 34                           5.5                 579                   94.5               5      100.0   34     5.5    584    94.5          
  Higher protection                                                                                      140                          22.8                474                   77.2               5      100.0   140    22.6   479    77.4          

**Abbreviation:** A/P, atovaquone/proguanil combination.

###### 

Adverse effects experienced by travelers on atovaquone/proguanil chemoprophylaxis

                                                          Habitual traveler   First-time traveler   Total                                                
  -------------------------------------- ---------------- ------------------- --------------------- ------- --- ----- ------ -- ---- ------ ------ -- -- --
  Specify adverse side-effects, if any   Abdominal pain   61                  66.3                              24    88.9           85     71.4         
  Headache                               14               15.2                                              2   7.4             16   13.4                
  Nausea                                 14               15.2                                              1   3.7             15   12.6                
  Other                                  3                3.3                                                                   3    2.5                 
